Gregg Gonsalves

Last updated

Gregg Gonsalves
Born (1963-10-21) October 21, 1963 (age 60)
Mineola, New York, United States
Alma mater
Occupation(s)Health activist (HIV/AIDS, opioid crisis, COVID-19), epidemiologist
Employer(s) Yale School of Public Health and Yale Law School
Known for ACT UP New York Treatment Action Group, Yale Global Health Justice Partnership
Awards

Gregg Gonsalves (born October 21, 1963) is a global health activist, an epidemiologist, an associate professor at Yale School of Public Health and an associate professor (adjunct) at Yale Law School. [1] [2] As well as being co-director of Yale Law School's Global Health Justice Partnership, [2] Gonsalves is the public health correspondent of the progressive magazine The Nation . [3]

Contents

Early life

He was born in Mineola, New York, on October 21, 1963, grew up in nearby East Meadow, New York, and attended East Meadow High School. [4] [5] His parents were New York City school teachers, both of whom were born and grew up in Brooklyn, New York, with his father's family originally from Madeira and his mother's family from Sicily. [6] He attended Tufts University starting in 1981, but dropped out before finishing his BA degree in English and American literature and Russian language and literature. [7] He has two sisters, Carin Gonsalves, a physician in Philadelphia, [8] and Dana Gonsalves, a commercial artist in New York City. [9]

Career

He began working with the AIDS Coalition to Unleash Power (ACT UP) in 1990, going on to co-found the Treatment Action Group (TAG) in 1992, with his colleagues from the Treatment and Data Committee of ACT UP New York, including Peter Staley, Mark Harrington, and Spencer Cox. With TAG, he authored several reports on HIV research, including a critical review of AIDS research at the National Institutes of Health, which led to a reorganization of the NIH's AIDS program by Congress. [10] [11] He found out he was HIV+ in 1995. [12] In 2000, Gonsalves went on to join Gay Men's Health Crisis and its Department of Public Policy. [13] In 2006, Gonsalves moved to Cape Town to work for the AIDS and Rights Alliance for Southern Africa where he was part of campaigns to expand access to antiretroviral therapy in Southern Africa. [14] In the mid-2000s, he gave well-regarded plenary speeches at two back-to-back International AIDS Conferences in Toronto and Mexico City. [15] [16] He is also a co-founder of the International Treatment Preparedness Coalition, a collective of AIDS activists from around the world fighting for access to AIDS treatment and other life-saving medicines through education, monitoring and advocacy. [17] In 2008, he received $100,000 as the first recipient of the AIDS Leadership Award from the John M. Lloyd Foundation. [18]

In 2008, he enrolled in Yale College as part of the Eli Whitney Students Program and obtained a BS with distinction in Ecology and Evolutionary Biology in 2011. From 2011 to 2012, he was an Open Society Foundations Fellow comparing social movements on AIDS, tuberculosis and maternal health in South Africa, Brazil and Ukraine. [19] In 2012, he enrolled in a Ph.D. program in the Epidemiology of Microbial Diseases at Yale School of Public Health and Yale Graduate School of Arts and Sciences obtaining a PhD in 2017, where he also co-founded the Yale Global Health Justice Partnership, the first collaboration between the public health and law schools at Yale. [20] He writes regularly for the popular press and has contributed op-eds and articles to The New York Times , The Washington Post , Foreign Policy and The Nation . [21] [22] [23] [24] [25] [26] He joined the faculty of Yale School of Public Health in July 2017. His research focuses on using quantitative models to improve the delivery of services and shape policy-making on HIV/AIDS. [27] [28] [29] [30] At Yale, he is affiliated with the Public Health Modeling Unit Archived February 22, 2020, at the Wayback Machine and the Yale Program in Addiction Medicine. In 2019, he received an Avenir award from the National Institute on Drug Abuse, a grant program devoted "to early-stage investigators who propose highly innovative studies [and] researchers who represent the future of addiction science" for his proposal to examine the syndemic of HIV, hepatitis C and overdose in the context of the US opioid crisis. [31]

Awards and honors

In 2008, he won the John M. Lloyd Foundation's inaugural AIDS Leadership Award. [32] Gonsalves and Mark Harrington are the only two AIDS activists to ever receive a MacArthur Fellowship, commonly but unofficially known as the "Genius Grant". [33] The two worked together and were members of ACT UP and TAG. [34] [35]

See also

Related Research Articles

<span class="mw-page-title-main">HIV/AIDS in the United States</span> HIV/AIDS epidemic in the United States

The AIDS epidemic, caused by HIV, found its way to the United States between the 1970s and 1980s, but was first noticed after doctors discovered clusters of Kaposi's sarcoma and pneumocystis pneumonia in homosexual men in Los Angeles, New York City, and San Francisco in 1981. Treatment of HIV/AIDS is primarily via the use of multiple antiretroviral drugs, and education programs to help people avoid infection.

<span class="mw-page-title-main">ACT UP</span> International AIDS activism, direct action and advocacy group

AIDS Coalition to Unleash Power is an international, grassroots political group working to end the AIDS pandemic. The group works to improve the lives of people with AIDS through direct action, medical research, treatment and advocacy, and working to change legislation and public policies.

<span class="mw-page-title-main">Treatment Action Campaign</span> South African HIV/AIDS activist organization

The Treatment Action Campaign (TAC) is a South African HIV/AIDS activist organisation which was co-founded by the HIV-positive activist Zackie Achmat in 1998. TAC is rooted in the experiences, direct action tactics and anti-apartheid background of its founder. TAC has been credited with forcing the reluctant government of former South African President Thabo Mbeki to begin making antiretroviral drugs available to South Africans.

<span class="mw-page-title-main">Peter Piot</span> Belgian microbiologist (born 1949)

Sir Peter Karel, Baron Piot, is a Belgian-British microbiologist known for his research into Ebola and AIDS.

This is a timeline of HIV/AIDS, including cases before 1980.

<span class="mw-page-title-main">Epidemiology of HIV/AIDS</span> Epidemic of HIV/AIDS

The global epidemic of HIV/AIDS began in 1981, and is an ongoing worldwide public health issue. According to the World Health Organization (WHO), by 2023, HIV/AIDS had killed approximately 40.4 million people, and approximately 39 million people were infected with HIV globally. Of these 29.8 million people, 75% are receiving antiretroviral treatment. There were about 630,000 deaths from HIV/AIDS in 2022. The 2015 Global Burden of Disease Study estimated that the global incidence of HIV infection peaked in 1997 at 3.3 million per year. Global incidence fell rapidly from 1997 to 2005, to about 2.6 million per year. Incidence of HIV has continued to fall, decreasing by 23% from 2010 to 2020, with progress dominated by decreases in Eastern Africa and Southern Africa. As of 2020, there are approximately 1.5 million new infections of HIV per year globally.

amfAR Nonprofit AIDS research organization

amfAR, the Foundation for AIDS Research, known until 2005 as the American Foundation for AIDS Research, is an international nonprofit organization dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of AIDS-related public policy.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

Infection with HIV, a retrovirus, can be managed with treatment but without treatment can lead to a spectrum of conditions including AIDS.

<span class="mw-page-title-main">HIV/AIDS in Canada</span>

HIV/AIDS was first detected in Canada in 1982. In 2018, there were approximately 62,050 people living with HIV/AIDS in Canada. It was estimated that 8,300 people were living with undiagnosed HIV in 2018. Mortality has decreased due to medical advances against HIV/AIDS, especially highly active antiretroviral therapy (HAART).

Mark Harrington is an HIV/AIDS researcher, a staunch activist for HIV/AIDS and tuberculosis awareness, and the co-founder and policy director of the Treatment Action Group (TAG). After graduating from Harvard University in 1983, Harrington spent time exploring and did not commit to one specific career. When the AIDS epidemic became personal for Harrington, and close friends were being infected with HIV, he decided to take action and joined the group, AIDS Coalition to Unleash Power or ACT UP. As part of the Treatment and Data Committee of ACT UP, Harrington fostered relationships with government officials associated with AIDS research. Eventually differences in opinions on how to best advocate for HIV/AIDS research led to Harrington and other members of ACT UP leaving to start their own group, TAG. With TAG, Harrington was able to create influential and meaningful policy regarding HIV/AIDS research and he worked closely with the NIH, WHO, and other government organizations. Over the years Harrington has distinguished himself as an adept scientist and reputable researcher in his own right. Currently he is published in multiple scientific journals and continues to be an advocate for those with HIV and TB around the world.

Discrimination against people with HIV/AIDS or serophobia is the prejudice, fear, rejection, and stigmatization of people with HIV/AIDS. Marginalized, at-risk groups such as members of the LGBTQ+ community, intravenous drug users, and sex workers are most vulnerable to facing HIV/AIDS discrimination. The consequences of societal stigma against PLHIV are quite severe, as HIV/AIDS discrimination actively hinders access to HIV/AIDS screening and care around the world. Moreover, these negative stigmas become used against members of the LGBTQ+ community in the form of stereotypes held by physicians.

Aidsmap, also known as NAM aidsmap, is a website which publishes independent, accurate and accessible information and news about HIV and AIDS. The aidsmap website is run by a charity based in the United Kingdom, NAM.

The cost of HIV treatment is a complicated issue with an extremely wide range of costs due to varying factors such as the type of antiretroviral therapy and the country in which the treatment is administered. The first line therapy of HIV, or the initial antiretroviral drug regimen for an HIV-infected patient, is generally cheaper than subsequent second-line or third-line therapies. There is also a great variability of drug prices among low, middle, and high income countries. In general, low-income countries have the lowest cost of antiretroviral therapy, while middle- and high-income tend to have considerably higher costs. Certain prices of HIV drugs may be high and difficult to afford due to patent barriers on antiretroviral drugs and slow regulatory approval for drugs, which may lead to indirect consequences such as greater HIV drug resistance and an increased number of opportunistic infections. Government and activist movements have taken efforts to limit the price of HIV drugs.

<span class="mw-page-title-main">Quarraisha Abdool Karim</span>

Quarraisha Abdool Karim is an infectious diseases epidemiologist and co-founder and Associate Scientific Director of CAPRISA. She is a Professor in Clinical Epidemiology, Columbia University, New York and Pro-Vice Chancellor for African Health, University of KwaZulu-Natal, South Africa.

<span class="mw-page-title-main">Salim Abdool Karim</span> South African medical researcher

Salim S. Abdool Karim, MBChB, MMed, MS(Epi), FFPHM, FFPath (Virol), DipData, PhD, DSc(hc), FRS is a South African public health physician, epidemiologist and virologist who has played a leading role in the AIDS and COVID-19 pandemic. His scientific contributions have impacted the landscape of HIV prevention and treatment, saving thousands of lives.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

<span class="mw-page-title-main">Kenyon Farrow</span> LGBTQ and HIV/AIDS activist


Kenyon Farrow is an American writer, activist, director, and educator focused on progressive racial and economic justice issues related to the LGBTQ community. He served as the executive director of Queers for Economic Justice, policy institute fellow with National LGBTQ Task Force, U.S. & Global Health Policy Director of Treatment Action Group, public education and communications coordinator for the New York State Black Gay Network, senior editor with TheBody.com and TheBodyPro.com, and co-executive director of Partners for Dignity and Rights. In 2021, Farrow joined PrEP4All as managing director of advocacy & organizing.

<span class="mw-page-title-main">HIV/AIDS activism</span> Social movement advocating for a societal response to HIV/AIDS

Social and political activism to raise awareness about HIV/AIDS, as well as to raise funds for effective treatment and care of people with AIDS (PWAs), has taken place in multiple nations across the world since the 1980s. As a disease that began in marginalized populations, efforts to mobilize funding, treatment, and fight discrimination have largely been dependent on the work of grassroots organizers directly confronting public health organizations as well as politicians, drug companies, and other institutions.

<span class="mw-page-title-main">Adaora Adimora</span> Professor of Medicine and epidemiology

Adaora Alise Adimora is an American doctor and academic. She is the Sarah Graham Kenan Distinguished Professor of Medicine and professor of epidemiology at the University of North Carolina School of Medicine. Her research centers on the transmission of HIV, as well as other sexually transmitted infections (STIs), among minority populations. Her work has highlighted the importance of social determinants of HIV transmission and the need for structural interventions to reduce risk. In 2019, she became an elected member of the National Academy of Medicine in recognition of her contributions.

Fatima Hassan is a South African human rights lawyer who works in the field of health justice.

References

  1. ↑ "Gregg Gonsalves, PhD". Yale School of Public Health . Retrieved July 27, 2018.
  2. 1 2 "Gregg Gonsalves". Yale Law School . Retrieved December 30, 2019.
  3. ↑ "Gregg Gonsalves". The Nation . September 24, 2015. Retrieved February 12, 2022.
  4. ↑ Shufro, Cathy (September–October 2015). "Its not just the germs". Yale Alumni Magazine. Retrieved July 27, 2018.
  5. ↑ "Foundation honors LI native as 'genius'". Newsday . October 10, 2018. Retrieved December 30, 2019.
  6. ↑ Beaubien, Jason (October 4, 2018). "A Global Health Evangelist Is Shocked To Hear He's A 'Genius'". NPR . Retrieved January 2, 2019.
  7. ↑ "Tufts Magazine Archive Summer 2004". Tufts University . Retrieved December 30, 2019.
  8. ↑ "Carin F. Gonsalves, MD". Jefferson University Hospital . Retrieved December 30, 2019.
  9. ↑ "How lucky am I? I get to spend my days doing what I love to do — designing with a purpose, bringing together great storytelling and design". Sequel Studio. Retrieved December 30, 2019.
  10. ↑ Brown, Phyllida. "The hour of the activist: AIDS campaigners in the US are changing the way the nation's research into HIV is organised. Will other diseases get the same treatment?". New Scientist . Retrieved December 30, 2019.
  11. ↑ "TAG at 20: Early Campaigns". Treatment Action Group . Retrieved December 30, 2019.
  12. ↑ "AIDS at 30: an interview with activist Gregg Gonsalves". Science Speaks: Global ID News. May 20, 2011. Retrieved July 27, 2018.
  13. ↑ "AIDS Activist Gregg Gonsalves Honored". POZ. March 27, 2008. Retrieved December 30, 2019.
  14. ↑ Mbali, M. (March 29, 2013). South African AIDS Activism and Global Health Politics. Springer. ISBN   978-1-137-31216-7.
  15. ↑ "The ACT UP Historical Archive: Gonsalves speech: Reflecting Back and Looking Forward". ACT UP NYC. Retrieved December 30, 2019.
  16. ↑ Mykhalovskiy, Eric; Brown, Glen; Kort, Rodney (October 6, 2009). "XVII International AIDS Conference: From Evidence to Action - Social, behavioural and economic science and policy and political science". Journal of the International AIDS Society. 12 (Suppl 1): S5. doi: 10.1186/1758-2652-12-S1-S5 . ISSN   1758-2652. PMC   2759034 . PMID   19811671.
  17. ↑ "Home". International Treatment Preparedness Coalition. Retrieved December 30, 2019.
  18. ↑ "Leadership and AIDS: Gregg Gonsalves". UNAIDS. May 9, 2008. Retrieved November 4, 2010.
  19. ↑ "Gregg Gonsalves - Open Society Fellowship". Open Society Foundations . Retrieved December 30, 2019.
  20. ↑ "Gregg Gonsalves Co-founds Law School/Public Health Partnership" (Press release). Yale Graduate School of Arts and Sciences. December 2, 2014. Retrieved June 2, 2020.
  21. ↑ Gonsalves, Gregg (October 28, 2014). "Stop Playing Cowboy on Ebola". Foreign Policy . Retrieved February 22, 2020.
  22. ↑ Gonsalves, Gregg (May 9, 2017). "We've Got to ACT UP to Stop Trumpcare". The Nation . ISSN   0027-8378 . Retrieved February 22, 2020.
  23. ↑ Gonsalves, Gregg; Harrington, Mark; Kessler, David A. (June 11, 2015). "Opinion: Don't Weaken the F.D.A.'s Drug Approval Process". The New York Times . ISSN   0362-4331 . Retrieved February 22, 2020.
  24. ↑ Gonsalves, Gregg (January 14, 2011). "Obama's zero-sum game in the fight against AIDS". The Washington Post . ISSN   0190-8286 . Retrieved February 22, 2020.
  25. ↑ Gonsalves, Gregg (March 9, 2019). "This is Not A Cure for My H.I.V." The New York Times . ISSN   0362-4331 . Retrieved February 22, 2020.
  26. ↑ Gonsalves, Gregg (February 8, 2019). "The U.S. really could end AIDS — if the Trump administration gets out of the way". The Washington Post . Retrieved February 22, 2020.
  27. ↑ Gonsalves, Gregg S.; Copple, J. Tyler; Johnson, Tyler; Paltiel, A. David; Warren, Joshua L. (September 3, 2018). "Bayesian adaptive algorithms for locating HIV mobile testing services". BMC Medicine. 16 (1): 155. doi: 10.1186/s12916-018-1129-0 . ISSN   1741-7015. PMC   6120098 . PMID   30173667.
  28. ↑ Gonsalves, Gregg S; Crawford, Forrest W (October 1, 2018). "Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011–15: a modelling study". The Lancet HIV . 5 (10): e569–e577. doi:10.1016/S2352-3018(18)30176-0. ISSN   2352-3018. PMC   6192548 . PMID   30220531.
  29. ↑ Gonsalves, Gregg; Paltiel, A.; Cleary, Paul; Gill, Michael; Kitahata, Mari; Rebeiro, Peter; Silverberg, Michael; Horberg, Michael; Abraham, Alison; Althoff, Keri; Moore, Richard (August 15, 2017). "A Flow-Based Model of the HIV Care Continuum in the United States". Journal of Acquired Immune Deficiency Syndromes. 75 (5): 548–553. doi:10.1097/QAI.0000000000001429. ISSN   1525-4135. PMC   5533168 . PMID   28471841.
  30. ↑ Gonsalves, Gregg S.; Crawford, Forrest W.; Cleary, Paul D.; Kaplan, Edward H.; Paltiel, A. David (February 1, 2018). "An Adaptive Approach to Locating Mobile HIV Testing Services". Medical Decision Making. 38 (2): 262–272. doi:10.1177/0272989X17716431. ISSN   0272-989X. PMC   5748375 . PMID   28699382.
  31. ↑ "Avenir Award Winners". National Institute on Drug Abuse. October 15, 2019. Retrieved December 30, 2019.
  32. ↑ "John M. Lloyd AIDS Leadership Award". John M. Lloyd Foundation . Retrieved December 30, 2019.
  33. ↑ Stannard, Ed (October 5, 2018). "2 from New Haven with Yale ties win $625,000 MacArthur 'genius' grants". New Haven Register . Retrieved October 12, 2018.
  34. ↑ "Gregg Gonsalves". MacArthur Foundation. October 5, 2018. Retrieved October 12, 2018.
  35. ↑ Staley, Peter (2021). Never Silent. Chicago Review Press. p. 179. ISBN   9781641601429.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.